|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10792271||SINTETICA SA||Topical formulations of chloroprocaine and methods of using same|| |
(14 years from now)
Iheezo is owned by Sintetica Sa.
Iheezo contains Chloroprocaine Hydrochloride.
Iheezo has a total of 1 drug patent out of which 0 drug patents have expired.
Iheezo was authorised for market use on 27 September, 2022.
Iheezo is available in gel;ophthalmic dosage forms.
Iheezo can be used as method of inducing ocular anesthesia.
The generics of Iheezo are possible to be released after 15 September, 2038.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Product (NP)||Sep 27, 2025|
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic